Watch Ticker

None

Go to None Website

(%)

Live

$1.47

$ - $

$ - $

$

None

...

Watchers

Visitors

Zacks Equity Research - Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Related tickers: BMRN, EPZM, APTX, INZY.

Read Full Article

Zacks Equity Research - Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

Related tickers: NVAX, EPZM, SESN.

Read Full Article

Please sign in to view